May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
SnET2 Photodynamic Therapy for Age–Related Macular Degeneration: Safety Results From Two Parallel Phase III Trials
Author Affiliations & Notes
  • C.D. Regillo
    Retina Service, Wills Eye Hosp, Philadelphia, PA
  • SnET2 Study Group
    Retina Service, Wills Eye Hosp, Philadelphia, PA
  • Footnotes
    Commercial Relationships  C.D. Regillo, Miravant Medical Technologies C.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3190. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.D. Regillo, SnET2 Study Group; SnET2 Photodynamic Therapy for Age–Related Macular Degeneration: Safety Results From Two Parallel Phase III Trials . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3190.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To present adverse event and other safety data from two Phase III randomized trials evaluating SnET2–PDT over a 2–year period for the treatment of subfoveal CNV secondary to AMD. Methods: Two identical phase III trials evaluated a total of 920 patients. SnET2 doses of 0.5 mg/kg (N=372), 0.75 mg/kg (N=365) or placebo (N=183) were administered to patients approximately 12 minutes prior to 36 J/cm2 light activation, with re–treatment possible every 13 weeks. Adverse events were coded using the WHO–Adverse Reaction Terminology Dictionary and their severity and relationship to treatment were determined by the investigators. Results: The most common adverse events were vision disorders, with incidence similar between the treatment groups and placebo. The most common non–visual event was transient, mild skin photosensitivity, with incidence rates of 1.1, 4.9 and 11.2 events per 100 administrations of placebo, 0.5 and 0.75 mg/kg respectively. The incidence of application site AEs was 1.6, 5.1 and 8.3 percent of total administrations for placebo, 0.5, and 0.75 mg/kg doses respectively. Cumulative exposure to SnET2 (as a consequence of retreatment) was not associated with increased incidence of dermal photosensitivity or application site reactions. Extremely low incidences of infusion–related back pain (placebo=0.22%, 0.5 mg/kg=0.23%, 0.75 mg/kg=0.11%) and acute post–treatment vision loss (placebo=0.22%, 0.5 mg/kg =0.11%, 0.75 mg/kg=0.45%) were reported. Incidence of treatment–related SAEs was also extremely low, occurring in only 4 of 920 patients. These consisted of 1 extravasation following a dose of 0.5 mg/kg and 2 extravasations and 1 allergic reaction following doses of 0.75 mg/kg. Conclusions: The proposed clinical dose of 0.5 mg SnET2/kg was well–tolerated with an excellent safety profile in this patient group.

Keywords: photodynamic therapy • choroid: neovascularization • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×